Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$1.70B+974.37%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Said Samih Taleb Darwazah
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 9,400
- Beta
- 0.65
- Country
- GB
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.52
Financials
Revenue
$1.70B+974.4%Net Income
$219.77M+685.5%EBITDA
$475.03M+922.5%Free Cash Flow
$46.32MEPS (diluted)
$1.01+535.2%Shares Outstanding (diluted)
218.63M+24.3%Operating Expenses
$362.68MCash & Debt
$288.66MReturn of Capital
$276.93MDividend per Share
$0.38Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.35B | $410.94M | $1.86 |
| 2024 | $3.13B | $359.00M | $1.62 |
| 2023 | $2.88B | $190.00M | $0.85 |
| 2022 | $2.52B | $188.00M | $0.84 |
| 2021 | $2.55B | $421.00M | $1.82 |
| 2020 | $2.34B | $431.00M | $1.83 |
| 2019 | $2.21B | $486.00M | $2.01 |
| 2018 | $2.07B | $282.00M | $1.17 |
| 2017 | $1.94B | $-843.00M | $-3.51 |
| 2016 | $1.95B | $155.00M | $0.67 |
| 2015 | $1.44B | $252.00M | $1.27 |
| 2014 | $1.49B | $278.00M | $1.40 |
| 2013 | $1.36B | $212.00M | $1.08 |
| 2012 | $1.11B | $100.00M | $0.51 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from HKMPF's reported EPS growth of 10.5% a year over 13 years.
- EPS in 5 years
- $3.07
- Implied price
- $33.76
- Return from $19.07
- 12.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $16.78 — -12.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 7 | 9 | 11 | 13 | 15 |
|---|---|---|---|---|---|
| 0.5% | -6.9% | -2.1% | 2.0% | 5.4% | 8.5% |
| 5.5% | -2.2% | 2.8% | 7.0% | 10.7% | 13.9% |
| 10.5% | 2.4% | 7.7% | 12.1% | 15.9% | 19.3% |
| 15.5% | 7.0% | 12.6% | 17.2% | 21.2% | 24.7% |
| 20.5% | 11.7% | 17.4% | 22.2% | 26.4% | 30.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
105+10.53%Social Signal Score
Mentions (4)
- Newsproactiveinvestors.co.uk·31d ago·Neutral
Panmure Liberum raises Hikma target price to 1,900p Panmure Liberum has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) from 1,600p to 1,900p, saying the drugmaker's strong first-half results support further upside in its shares. The broker said Hikma's recent interim results were reassuring, with the only surprises coming on the upside and beats reported across the business.
View source ↗ - Newsproactiveinvestors.co.uk·41d ago·Positive
Jefferies lifts Hikma target as CMO deal underpins growth story Jefferies has raised its price target on Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,025p from 1,870p, pointing to the expanding contract manufacturing business as the source of the upgrade. The 'buy' rating is unchanged, with the new target implying 24% upside from Tuesday's share price of 1,633p (flat).
View source ↗ - Newsproactiveinvestors.co.uk·55d ago·Neutral
Citi sees Hikma discount as unwarranted after upgrade to forecasts Citi has raised its estimates for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) following stronger-than-expected half-year results, arguing that the FTSE 100 drugmaker's valuation discount is no longer justified. Ephrem Ravi reiterated a buy rating and set a new price target of £18.70.
View source ↗ - Newsproactiveinvestors.co.uk·56d ago·Neutral
Hikma boost as broker raises price target Deutsche Bank has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,050p from 1,950p, reiterating its 'buy' rating on the FTSE 100 drugmaker. Kane Slutzkin said Hikma delivered a substantial beat at the half-year stage, driven primarily by the branded division, yet left full-year guidance largely unchanged.
View source ↗
Earnings
Thu, Feb 25(in 5 months)
Consensus estimate $1.13 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$1.26 vs $1.10beat
- Thu, Feb 26$1.08 vs $1.08beat
- Thu, Aug 7$1.07 vs $1.22miss
- Thu, Apr 25$0.27 vs $0.96miss
- Thu, Aug 3$1.28 vs $0.95beat
Estimates and results for HKMPF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in HKMPF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.